Notice: This company has been marked as potentially delisted and may not be actively trading. Jupiter Neurosciences (JUNS) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsCompetitorsTrends Get the Latest News and Ratings for JUNS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Jupiter Neurosciences and its competitors. Enter your email to sign up for newsletter Sign Up JUNS Analyst Ratings Over TimeTypeCurrent Forecast12/23/23 to 12/22/241 Month Ago11/23/23 to 11/22/243 Months Ago9/24/23 to 9/23/241 Year Ago12/23/22 to 12/23/23Strong Buy1 Strong Buy rating(s) N/A N/A N/A Buy0 Buy rating(s) N/A N/A N/A Hold0 Hold rating(s) N/A N/A N/A Sell0 Sell rating(s) N/A N/A N/A Consensus Price TargetN/AN/AN/AN/AForecasted UpsideN/AN/AN/AN/AConsensus RatingStrong BuyN/AN/AN/A 70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << JUNS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History JUNS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Jupiter Neurosciences Stock vs. The CompetitionTypeJupiter NeurosciencesMedical CompaniesS&P 500Consensus Rating Score 4.00 2.81 2.51Consensus RatingStrong BuyModerate BuyModerate BuyPredicted UpsideN/A25,828.59% Upside14.53% UpsideNews Sentiment RatingPositive NewsSee Recent JUNS NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails12/19/2024Greenridge Global1 of 5 starsW. GregozeskiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-BuyAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 09:25 AM ET. JUNS Forecast - Frequently Asked Questions Should I buy or sell Jupiter Neurosciences stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jupiter Neurosciences in the last year. There is currently 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "strong buy" JUNS shares. Does Jupiter Neurosciences's stock price have much downside? According to analysts, Jupiter Neurosciences's stock has a predicted downside of -100.00% based on their 12-month stock forecasts. Has Jupiter Neurosciences been upgraded by Wall Street analysts recently? Over the previous 90 days, Jupiter Neurosciences's stock had 1 upgrade by analysts. What analysts cover Jupiter Neurosciences? Jupiter Neurosciences has been rated by research analysts at Greenridge Global in the past 90 days. Do Wall Street analysts like Jupiter Neurosciences more than its competitors? Analysts like Jupiter Neurosciences more than other "medical" companies. The consensus rating for Jupiter Neurosciences is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how JUNS compares to other companies. Stock Forecasts and Research Tools Related Companies Pharvaris Stock Forecast Eli Lilly and Company Stock Forecast Novo Nordisk A/S Stock Forecast Johnson & Johnson Stock Forecast AbbVie Stock Forecast Merck & Co., Inc. Stock Forecast AstraZeneca Stock Forecast Novartis Stock Forecast Abbott Laboratories Stock Forecast Pfizer Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter 70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << This page (NASDAQ:JUNS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.